ADRX vs KRSA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ADRX · Adarx Pharmaceuticals$13.23 ▼ 0.45%
KRSA · Korsana Biosciences$31.05 ▲ 2.04%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ADRX -31.6%
- KRSA +0.2%
Head to head
| Metric | ADRX | KRSA |
|---|---|---|
| Price | $13.23 | $31.05 |
| Change today | ▼ 0.45% | ▲ 2.04% |
| Market cap | $1.35B | $1.41B |
| Return, 3 months | – | +23.9% |
| Return, year to date | – | +249.3% |
| Return, 1 year | – | +173.5% |
| P/E (TTM) | – | – |
| P/B | -5.4 | 3.6 |
| P/E percentile vs own 5y | 87th | 87th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +258.7% | – |
| Net profit growth (YoY) | -42.4% | – |
| Gross margin | – | – |
| Operating margin | -1,735.0% | – |
| Net margin | -1,434.1% | – |
| Return on equity | – | – |
| Analyst target vs. price | +164.6% | +70.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 22 | 49 |
| 30-day volatility | 60.6% | 66.5% |
| Max drawdown, 1 year | -35.9% | -54.7% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KRSA is the largest of the group by market value.
- ADRX has been the calmest stock over the last 30 days.